The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment – DocWire News

A research team from the University of Houston has found a way to use the stem cells found in fat and guide it to become a pacemaker-like cell, according to a new study.

We are reprogramming the cardiac progenitor cell and guiding it to become a conducting cell of the heart to conduct electrical current, said study co-author Bradley McConnell, associate professor of pharmacology, in a press release

The team, publishing the study in the Journal of Molecular and Cellular Cardiology, worked on converting adipogenic mesenchymal stem cells, which reside within fat cells, into cardia progenitor cells. The ensuing cardiac progenitor cells can be programmed to aid heartbeats as a sinoatrial node (SAN), which is part of the electrical cardiac conduction system.

The researchers used what they called a standard screening strategy to test for reprogramming factors for converting human cardiac progenitor cells into pacemaker-like cells. According to their study results, the authors observed expressions of many pacemaker-specific genes, including CX30.2, KCNN4, HCN4, HCN3, HCN1, and SCN3b. The authors wrote that SHOX2, HCN2, and TBX5 (SHT5) combinations of transcription factors were much better candidate(s) in driving cardiac progenitor cells into pacemaker-like cells than other combinations and single transcription factors.

Results of this study show that the SHT5 combination of transcription factors can reprogram CPCs into Pacemaker-like cells, they wrote in their conclusion. SHT5 may be used as a potential stem cell therapy for sick sinus syndrome (SSS) and for other cardiac conduction diseases.

Visit link:
The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment - DocWire News

Study of the 3D Cell Culture Market in Asia-Pacific, 2019-2027: Projecting a 13.11% CAGR, Driven by Promising Developments Using Regenerative Medicine…

Dublin, Dec. 23, 2019 (GLOBE NEWSWIRE) -- The "Asia-Pacific 3D Cell Culture Market 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Research conducted shows the 3D cell culture market in the Asia-Pacific would be fast progressing in terms of revenue, with a CAGR of 13.11% over the forecasting years 2019-2027.

India, Japan, China, South Korea, Australia & New Zealand, ASEAN countries and Rest of APAC countries together constitute the Asia-Pacific 3D cell culture market.

Several R&D projects are being initiated in South Korea to cater to the rising demand for stem cell therapies and regenerative medicine. In September 2017, the Cell Therapy World Asia 2017 was held in the country. Several cell therapy companies in Asia gathered for the conference to discuss the best practices & innovations in this field. Such factors are promoting the growth of the South Korean 3D cell culture market.

It has been anticipated that the 3D cell culture market in Japan would witness growth, owing to the country releasing new products in the market. Pluristem Therapeutics received a patent for their technology of using 3D cell culturing methods, that allow the creation of cell therapies from fat cells.

The Government of Japan has been focusing increasingly on Cell-based regenerative medicine, which indicates further advances in 3D cell culture technology over the projected period. In 2014, Japan-based Reprocell acquired Reinnervate Ltd., a spin-off of Durham University, agreeing to invest in the researches conducted in the university laboratories for scaffolding structures that support the growth of 3D cells.

COMPETITIVE OUTLOOK

The biggest brands in the 3D cell culture market are Merck KGaA, 3D Biotek, LLC, Thermo Fisher Scientific, Inc., Corning Inc., InSphero, Lonza Group AG, and Synthecon, Incorporated.

Key Topics Covered

1. Asia-Pacific 3D Cell Culture Market - Summary

2. Industry Outlook

2.1. Market Definition2.2. Porter'S Five Forces Model2.2.1. Threat Of New Entrants2.2.2. Threat Of Substitute2.2.3. Bargaining Power Of Buyers2.2.4. Bargaining Power Of Suppliers2.2.5. Threat Of Competitive Rivalry2.3. Economic Technological, And Political & Legal Outlook2.4. Regulatory Outlook2.5. Key Insight2.6. Market Attractiveness Index2.7. Market Drivers2.7.1. Growing Cancer Prevalence2.7.2. High Demand For Organ Transplantation2.7.3. Promising Developments Using Regenerative Medicine2.8. Market Restraints2.8.1. Lack Of Skilled Professionals2.8.2. Incompatibilities Of The Preferred Analytical Technologies With 3D Cell Culture2.9. Market Opportunities2.9.1. Increasing Usage Of 3D Cell Culture In Organ Transplantation And Drug Screening2.9.2. Technological Advancement2.10. Market Challenges2.10.1. Lack Of Availability Of Data For Research On 3D Cell Culture2.10.2. Challenges Associated With 3D Cell Culture In Performing Experiments

3. 3D Cell Culture Market Outlook - By Technology

3.1. Scaffold-Based3.1.1. Hydrogels3.1.2. Polymeric Scaffolds3.1.3. Micropatterned Surface Microplates3.2. Scaffold-Free3.2.1. Hanging Drop Microplates3.2.2. Spheroid Microplates Containing Ultra-Low Attachment (Ula) Coating3.2.3. Microfluidic 3D Cell Culture3.2.4. Magnetic Levitations & 3D Bioprinting3.3. 3D Bioreactors

4. 3D Cell Culture Market Outlook - By Application

4.1. Cancer4.2. Tissue Engineering & Immunohistochemistry4.3. Drug Development4.4. Stem Cell Research4.5. Other Applications

5. 3D Cell Culture Market Outlook - By Component

5.1. Media5.2. Reagents And Consumables

6. 3D Cell Culture Market Outlook - By End-User

6.1. Biotechnology And Pharmaceutical Organizations6.2. Research Laboratories And Institutes6.3. Hospitals And Diagnostic Centers6.4. Other End-Users

7. 3D Cell Culture Market - Regional Outlook

7.1. Asia-Pacific7.1.1. Country Analysis7.1.1.1. Japan7.1.1.2. China7.1.1.3. India7.1.1.4. Australia & New Zealand7.1.1.5. South Korea7.1.1.6. Asean Countries7.1.1.7. Rest Of Asia-Pacific

8. Company Profiles

8.1. Becton Dickinson And Company8.2. Tecan Group Ltd.8.3. Promocell Gmbh8.4. Corning Inc.8.5. Nano3D Biosciences, Inc.8.6. 3D Biotek, Llc8.7. Merck Kgaa8.8. Emulate8.9. Thermo Fisher Scientific, Inc.8.10. Ge Healthcare8.11. Insphero8.12. Lonza Group Ag8.13. Vwr Corporation8.14. Synthecon, Incorporated

For more information about this report visit https://www.researchandmarkets.com/r/reo3ym

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Visit link:
Study of the 3D Cell Culture Market in Asia-Pacific, 2019-2027: Projecting a 13.11% CAGR, Driven by Promising Developments Using Regenerative Medicine...

Stem Cells Market Poised to Expand at a Robust Pace Over 2017 to 2025 – Market Research Sheets

In theglobalstem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

Request PDF Sample of Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Enquiry for Discount on Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=132

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

This post was originally published on Market Research Sheets

Continue reading here:
Stem Cells Market Poised to Expand at a Robust Pace Over 2017 to 2025 - Market Research Sheets

Illuminating Christmas, 19 years and counting… in honour of the Anthony Nolan Charity – London News Online

The magic of Christmas comes in the form of fairy lights this year and stem cells.

Retired taxi driver Gunaltay Mustafa has illuminated his house with a 1,000-bulb Christmas display for the 19th year in a row.

The aim of his festive lights is to raise funds and awareness for Anthony Nolan, the charity that saved his sons life.

Anthony Nolan works to find matching stem cell donors for people with blood cancer and blood disorders.

Gunaltays son, Alex, was diagnosed with leukemia when he was four.

After three years of treatment he went into remission. When he was just 11, his leukemia returned for the second time.

Anthony Nolan searched the stem cell register and was able to find Alex a lifesaving stemcell match.

Thanks to the donor that was found by Anthony Nolan, Alex is now a healthy 24-year-old with his whole life ahead of him.

Mustafa said: Everyone in the area knows about the Christmas light house, and this year we have more lights than ever before.

The display brings a bit of Christmas cheer to Southwark every year, with the added intention of giving a little something back to Anthony Nolan.

It costs 40 for Anthony Nolan to add each new donor to the register, so the charity needs financial support to help it continue to give patients, their family and friends hope.

The charity also carries out pioneering research to increase stem cell transplant success, and supports patients through their transplant journeys.

Senior community fundraiser at Anthony Nolan, Beatrix Passmore, said: In raising funds and awareness, Gunaltay will help Anthony Nolan give blood cancer patients, like his son Alex, a second chance of life.

Excerpt from:
Illuminating Christmas, 19 years and counting... in honour of the Anthony Nolan Charity - London News Online

The global in vitro lung model market is expected to reach US$ 701.81 Mn in 2027 from US$ 185.80 Mn in 2018 – Yahoo Finance

NEW YORK, Dec. 23, 2019 /PRNewswire/ -- The global in vitro lung model market is expected to reach US$ 701.81 Mn in 2027 from US$ 185.80 Mn in 2018. The market is estimated to grow with a CAGR of 16.2% from 2019-2027.

Read the full report: https://www.reportlinker.com/p05833602/?utm_source=PRN

Driving factors of the in vitro lung model are significant growth in research funding, and increasing adoption of 3d model systems for in vitro studies.Also, growing research on lung diseases is likely to have a positive impact on the growth of the market in the coming years.

Besides, rising healthcare expenditure, and advancements in cell culture techniques is likely to have a positive effect on the growth of the market in the forecast years.The cases of asthma, lung cancer, and COPD has been growing across the globe at a significant rate.Thus there is a growing need to study lung diseases specifically.

Since early 2010's the practices of creating lab-grown organ buds, mostly referred to as 'organoids', have become more popular.These organ buds are miniature organ-like structures that are maintained in the lab, and researchers are able to grow these organoids, which resembles human body tissues.

Lung diseases, like idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), is a significant cause of death and illness worldwide.A recently published report by Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California developed a new system for building lung 3D organoids to model lung disease.

Moreover, Lung cancer cell lines have made a significant contribution to lung cancer research and biomedical discovery. The high similarities between lung cancer cell lines and the lung tumor helps in discovering new drug molecules. Thus the growing research on lung diseases is expected to offer broad growth opportunities for the in vitro lung model market at the global level.The global in vitro lung model market is segmented by type, and application.On the basis of type, the market is segmented into 2D and 3D.

The 3D segment is expected to dominate the type segment market as 3D cell culture gives better phenotypes insights which are poorly reproduced in conventional 2D cell culture, Based on the application, market is segmented into drug screening, toxicology, 3d model development, physiologic research, stem cell research, and regenerative medicine. Toxicology segment is expected to dominate the application segment during the forecast period.Some of the important primary and secondary sources included in the report are, Food and Drug Administration, World Health Organization (WHO), American Society of Clinical Oncology, American Type Culture Collection, Centers for Disease Control and Prevention, Canadian Lung Association and others.

Read the full report: https://www.reportlinker.com/p05833602/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-in-vitro-lung-model-market-is-expected-to-reach-us-701-81-mn-in-2027-from-us-185-80-mn-in-2018--300978999.html

SOURCE Reportlinker

Read the rest here:
The global in vitro lung model market is expected to reach US$ 701.81 Mn in 2027 from US$ 185.80 Mn in 2018 - Yahoo Finance

Global and Southeast Asia Embryonic Stem Cell Market 2013-2023 by Top Key Players, YoY Growth, Trends, Size, Share and Revenue Analysis – Market…

Kenneth Research recently published a detailed report on Global and Southeast Asia Embryonic Stem Cell Market which focuses on various market dynamics by providing in-depth details of the key market outlook factors, such as, market size and forecast, market segmentation and others for the forecast period 2013-2023. The report on Embryonic Stem Cell Market further portrays elaborated structure of the market which comprises of all necessary business-related information at global and regional levels. The information for the Embryonic Stem Cell Market is obtained from various sources, which are arranged and formulated according to the business need by our team of analysts and editors through the application of different methodological techniques and analytical tools, for instance, SWOT, PESTEL and others.

Request for Sample Copy of Business Report:https://www.kennethresearch.com/sample-request-10035836

The report also describes the key growth factors, drivers, opportunities and restraints, and depicts the competitive scenario of the Embryonic Stem Cell Market with detailed information regarding the segment of the market by Product, Trends, Technology, Top Key Players of Global Market, Distributors, Demand, Supply, Revenue and Sales Analysis and focuses on key statistics which includes market size and market value, Y-o-Y growth rate, CAGR, market share and others.

The report on Embryonic Stem Cell Market further examines the region wise growth for North America, Europe, Asia Pacific, Latin America and Middle East & Africa region and is further classified into:

Request for Sample Copy of Business Report:https://www.kennethresearch.com/sample-request-10035836

Competitive Analysis for Embryonic Stem Cell Market:

The leading key players studied in the Embryonic Stem Cell Market report includes Major Key Players of Global Market. These players are extensively engaged in the expansion of their customer base by implementing various strategies and ensuring ongoing process improvements, along with added investments for research and developments, so as to gain an extra edge in the competition.

Table of Content:

Chapter One Introduction of Embryonic Stem Cell Industry

Chapter Two Manufacturing Technology of Embryonic Stem Cell

Chapter Three Analysis of Global Key Manufacturers

Chapter Four 2013-2018 Global and Southeast Asia Market of Embryonic Stem Cell

Chapter Five Market Status of Embryonic Stem Cell Industry

Chapter Six 2018-2023 Market Forecast of Global and Southeast Asia Embryonic Stem Cell Industry

Chapter Seven Analysis of Embryonic Stem Cell Industry Chain

Chapter Eight Global and Southeast Asia Economic Impact on Embryonic Stem Cell Industry

Chapter Nine Market Dynamics of Embryonic Stem Cell Industry

Chapter Ten Proposals for New Project

Chapter Eleven Research Conclusions of Global and Southeast Asia Embryonic Stem Cell Industry

Tables and Figures Cont.

Request for Complete Details of This Business Report:https://www.kennethresearch.com/sample-request-10035836

About Kenneth Research:

Kenneth Research provides an extensive multi-client market research database with a non-exhaustive list of market research solutions that are aimed to meet the market demands of its clients across industry verticals, such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. One of the best rated reselling agencies for market research reports, our product portfolio includes key insights such as market sizing and market forecasting, market share analysis and key positioning of the players. Our team of analysts deliver their best expertise to enhance the knowledge of industry veterans and investors within the stipulated time for efficient strategy formulation and maximization of opportunity benefit.

Trending New Reports:

Chicory MarketChemotherapy-Induced Nausea and Vomiting (CINV) MarketChampagne MarketCell and Tissue Culture Supplies MarketCAT Scanner MarketCardiac Rhythm Management Devices MarketCancer Antibody Drug Conjugates MarketButter MarketBubble Milk Tea MarketBrewers Peptone Market

This post was originally published on Market Research Sheets

More:
Global and Southeast Asia Embryonic Stem Cell Market 2013-2023 by Top Key Players, YoY Growth, Trends, Size, Share and Revenue Analysis - Market...

Researchers Create Functional Mini-Liver by 3D Bioprinting – 3D Printing Progress

Using human blood cells, Brazilian researchers have succeeded in obtaining hepatic organoids ("mini-livers") that perform all of the liver's typical functions, such as producing vital proteins, storing vitamins, and secreting bile, among many others. The innovation permits the production of hepatic tissue in the laboratory in only 90 days and may in the future become an alternative to organ transplantation.

The study was conducted at the Human Genome and Stem Cell Research Center (HUG-CELL). Hosted by the University of So Paulo (USP), HUG-CELL is one of the Research, Innovation and Dissemination Centers (RIDCs) funded by So Paulo Research Foundation - FAPESP.

"More stages have yet to be achieved until we obtain a complete organ, but we're on the right track to highly promising results. In the very near future, instead of waiting for an organ transplant, it may be possible to take cells from the patient and reprogram them to make a new liver in the laboratory. Another important advantage is zero probability of rejection, given that the cells come from the patient," said Mayana Zatz, director of HUG-CELL and last author of the article published in Biofabrication.

The innovative part of the study resided in how the cells were included in the bioink used to produce tissue in the 3D printer. "Instead of printing individualized cells, we developed a method of grouping them before printing. These 'clumps' of cells, or spheroids, are what constitute the tissue and maintain its functionality much longer," said Ernesto Goulart, a postdoctoral fellow in USP's Institute of Biosciences and first author of the article.

The researchers thereby avoided a problem faced by most human tissue bioprinting techniques, namely, the gradual loss of contact among cells and hence loss of tissue functionality.

Spheroid formation in this study already occurred in the differentiation process, when pluripotent cells were transformed into hepatic tissue cells (hepatocytes, vascular cells, and mesenchymal cells). "We started the differentiation process with the cells already grouped together. They were cultured in agitation, and groups formed spontaneously," Goulart told Agncia FAPESP.

A liver in 90 days

The next stage consists of inducing differentiation into liver cells. The spheroids are then mixed with bioink, a hydrogel-like fluid, and printed out. The resulting structures mature in culture for 18 days.

"The printing process entails the deposition of spheroids along three axes, which is necessary for the material to gain volume and give the tissue proper support," Goulart said. "The gel-like bioink is crosslinked to make the structures more rigid so that they can be manipulated and even sutured."

Most of the available methods for printing live tissue use immersion and cell dispersion in a hydrogel to recapitulate the microenvironment and ensure tissue functionality. However, experiments have shown that loss of cell contact and functionality tends to occur when dispersion is performed cell by cell.

"It's a somewhat traumatic process for the cells, which need time to get used to the environment and acquire functionality," Goulart said. "At this stage, they aren't tissue yet because they're dispersed, but as shown by our study, they already have the capacity to clear the blood of toxins and to produce and secrete albumin (a protein produced only by the liver), for example."

In this study, researchers developed mini-livers using blood cells from three volunteers as raw material and compared markers relating to functionality, such as the maintenance of cell contact and protein production and release. "Our spheroids worked much better than those obtained from single-cell dispersion. As expected, during maturation, the markers of hepatic function were not reduced," Goulart said.

Although the study was limited to producing miniature livers, the technique can be used in the future to produce complete organs suitable for transplantation, according to Goulart. "We did it on a small scale, but with investment and interest, it can easily be scaled up," he said.

Source and top image: Fundacao de Amparo A Pesquisa Do Estado De Sao Paulo

Read more here:
Researchers Create Functional Mini-Liver by 3D Bioprinting - 3D Printing Progress

FY 2020 Government Funding Bill Repeals ACA Health-Related Taxes, Extends Expiring Health Provisions, Makes Other Health Policy Updates – Lexology

Congress has completed action on federal fiscal year (FY) 2020 spending, and President Trump has signed the two domestic and national security funding packages into law. The major health care policy provisions included in the domestic spending package, HR 1865, the Further Consolidated Appropriations Act, 2020 (the Act), are summarized below.

Repeal of ACA Device, Insurance Taxes

The Act permanently repeals the Affordable Care Acts (ACA) 2.3% excise tax on the sale of certain medical devices, which has been a top priority of the medical technology industry. It also permanently repeals the excise tax on certain high-cost employer-sponsored health coverage (the so-called Cadillac tax) and the annual excise tax imposed on health insurer providers.

Medicare Part B Policies

The Act incorporates provisions of the Laboratory Access for Beneficiaries (LAB) Act, which delays the next round of clinical laboratory private payer data reporting for one year. The Act also directs the Medicare Payment Advisory Commission (MedPAC) to study how to improve this data collection.

In addition, the Act excludes certain complex rehabilitative manual wheelchairs (e.g., HCPCS codes E1235, E1236, E1237, E1238, and K0008) from the Medicare durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) competitive bidding program. The Act also bars CMS from using competitive bidding rate information to adjust payment for certain wheelchair accessories and cushions furnished with complex rehabilitative manual wheelchairs.

The Act reimburses acute care hospitals on a reasonable cost basis for furnishing allogeneic hematopoietic stem cell transplants. It also extends outpatient hospital pass-through status for a number of diagnostic radiopharmaceuticals.

Medicare, Medicaid, and Public Health Extenders

The Act extends through May 22, 2020 a number of Medicare, Medicaid, and public health programs and policies, including the following:

In addition, the Act funds the Patient-Centered Outcomes Research Trust Fund through 2029, with a requirement that research projects consider a broader range of outcomes data and an expansion of research priorities to include research with respect to intellectual and developmental disabilities and maternal mortality. The Act also establishes Medicaid funding policy for the territories through FY 2021.

Other Health Policies

Other policies addressed by the Act include, among others:

Note that the Statement of Managers accompanying the Act also includes nonbinding requests that CMS review a wide range of reimbursement and other policies, such as air ambulance policy, reimbursement for innovative drugs, inefficiencies in the Recovery Audit program, telehealth coding, CMS innovation models, and Medicare Part D performance metrics.

Read more here:
FY 2020 Government Funding Bill Repeals ACA Health-Related Taxes, Extends Expiring Health Provisions, Makes Other Health Policy Updates - Lexology

Making advanced therapies takes industrializing personalization – STAT

Whats the best way to measure the real rate of progress in personalized cell therapies, gene therapies, and other advanced therapies?

Ive been tracking the ever-growing flow of reports about these therapies in scientific journals and press releases for 15 years, ever since I co-led the passage of Californias $3 billion Stem Cell Research and Cures Act in 2004.

But to truly gauge who will benefit from todays innovations, Ive learned I also need to study the stream of business and technology announcements that runs in parallel. That might seem more mundane but to veterans of advanced therapies, making the science work actually signals success for these gene-, tissue-, and cell-based advanced therapies.

advertisement

The reason is simple. My experience working with advanced therapies has taught me, time and again, that true next-generation medicine requires the industrialization of personalization. That sounds like an oxymoron, but it isnt. To create individualized therapeutics in a sustainable way, we need to deliver even if it seems counterintuitive mass customization.

Breakthroughs such as CAR-T cell therapies are inspiring. They are also unsustainably expensive, difficult to manufacture, and complicated to deliver. We can change this by creating a more focused cross-collaborative production and delivery ecosystem.

The Food and Drug Administration anticipates that it will approve 10 to 20 advanced therapies a year beginning in 2025. It also expects to receive up to 200 clinical trial applications for cell and gene therapies per year, starting now. The more than 1,000 advanced therapy clinical trials now underway worldwide could enroll almost 60,000 patients, according to the Alliance for Regenerative Medicine. That pace wont be possible without new systems and networks that reduce cost, simplify manufacturing, and streamline delivery.

I can see some of these on the horizon when I read the biotech and pharma partnerships reported in BioSpace and BioCentury. Of the 100 most recent, almost 10% were dedicated to cell- and gene-therapy companies and organizations. These partnership announcements are typically viewed as opportunities to highlight new business deals or contract wins. But they are also daily snapshots of the infrastructure of an evolving next-generation health care system forming from within. Here are just a few examples from 2019:

Its encouraging to see biopharma manufacturing, logistics, transport, and other partners in the cell- and gene-therapy ecosystem coming together in new ways to ensure the successful and reliable delivery of advanced therapies for individual patients. But much more evolution is needed to provide sustainable patient access to advanced therapies.

We need even more industry collaboration to overhaul and connect existing health care systems, so production and delivery of cell- and gene-based therapies can be more automated and affordable. According to estimates from credible industry colleagues and leaders, end-to-end automation can shave costs by at least 20% to 30%, and at the same time greatly improve predictability and patient safety.

We must also make this new world simpler for health care providers. Doctors and nurses must not only understand how advanced therapies work medically, but be able to order and deliver them safely with a minimum of delay or hassle. As noted in the New Yorker, CAR-T requires bringing a manufacturing lens to medicine. Supporting health care providers means creating true collaboration between digital technology providers, hospitals, logistics providers, biotech and pharma companies, and manufacturing, like the Boston initiative I described earlier.

Standardization is often decried as cookie-cutter medicine. In this space, however, it is the wave of the future.

While patient biology is unique, and each patients cells may produce a one-of-a-kind manufacturing batch, essential parts of the production and delivery process should be as predictable and easy as possible. One key place to start is in-process drug labeling. When patients cells become the raw material for advanced therapies, these labels become more complex and more necessary: When a patient is about to receive a cell therapy infusion, its essential that the name on the bag of genetically re-engineered cells is his or hers. The Standards Coordinating Body, an FDA-funded but independent nonprofit, is now leading an industry-wide labeling initiative for cell and gene therapies.

There are other clear signs that the advanced therapies field gets it when it comes to infrastructure needs, such as the inclusion of digital health and handling of patient data as categories of focus in the federal Cures 2.0 initiative currently circulating in Washington. But much remains to be done.

In centers caring for individuals with cancer and rare diseases, thousands of patients are today receiving advanced therapies that are transforming their lives. We need to make that possible for many, many more by working together to industrialize and personalize in parallel.

Amy DuRoss is the CEO and co-founder of Vineti, a digital technology company that provides next-generation software platforms for advanced therapies. Before that she was managing director for new business creation for GE Ventures, chief business officer at Navigenics, the co-founder and executive director of Proposition 71, Californias $3 billion stem cell research initiative that passed in 2004, and chief of staff at the resulting California Institute for Regenerative Medicine.

Read the original here:
Making advanced therapies takes industrializing personalization - STAT

Global Allogeneic Stem Cells Market 2020-2024 | Evolving Opportunities with Biosolution Co. Ltd. and Cynata Therapeutics Ltd. | Technavio – Yahoo…

Technavio has been monitoring the global allogeneic stem cells market and the market is poised to grow by USD 1.24 billion during 2020-2024 at a CAGR of over 12% during the forecast period. Request Free Sample Pages

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191218005455/en/

Technavio has announced its latest market research report titled global allogeneic stem cells market 2020-2024. (Graphic: Business Wire)

Read the 131-page research report with TOC on "Allogeneic Stem Cells Market Analysis Report by geography (Asia, Europe, North America, and ROW), by application (regenerative therapy and drug discovery and development), and segment forecasts, 2020-2024".

https://www.technavio.com/report/allogeneic-stem-cells-market-industry-analysis

The new product approvals and special drug designations are anticipated to boost the growth of the market. Based on the application, the allogeneic stem cells market has been segmented into regenerative therapy and drug discovery and development. Manufacturers are increasingly emphasizing innovations and improvisation in the development of regenerative therapies. Many of the regenerative therapeutic candidates have obtained approval for clinical trials in the US, Europe, and APAC due to the efficacy of allogeneic stem cell therapeutics. This is encouraging market players to launch new product lines to stimulate the overall product demand for stem or regenerative therapy using allogeneic stem cell therapeutics and provide better options for their customers. Thus, new product approvals are expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Allogeneic Stem Cells Market Companies:

Biosolution Co. Ltd.

Biosolution Co. Ltd. is headquartered in South Korea (Republic of Korea) and operates the business under its Unified business segment. The company offers an allogeneic keratinocyte spread medication, Keraheal-Allo, that promotes skin regeneration.

Cynata Therapeutics Ltd.

Cynata Therapeutics Ltd. is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sales of innovative therapeutics for the treatment of various diseases. The company provides a mesenchymal stem cell product, Cymerus, which is used to treat graft-versus-host disease.

JCR Pharmaceuticals Co. Ltd.

JCR Pharmaceuticals Co. Ltd. is headquartered in Japan and operates under two business segments, namely Pharmaceuticals, and Medical Devices and Laboratory Equipment. The company offers a regenerative medical product, TEMCELL HS Injection, which uses human mesenchymal stem cells for the treatment of acute graft-versus-host disease.

Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc. is headquartered in the US and offers products through its Unified business segment. The company provides OpRegen, which is currently being tested in a Phase I/IIa clinical trial. This product is intended for the treatment of dry AMD.

MEDIPOST Co. Ltd.

MEDIPOST Co. Ltd. is headquartered in South Korea (Republic of Korea) and offers products through its Unified business segment. The company provides an allogeneic umbilical cord blood-derived mesenchymal stem cell drug, CARTISTEM, which is used for the treatment of knee cartilage defects.

Story continues

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Allogeneic Stem Cells Application Outlook (Revenue, USD Million, 2020-2024)

Allogeneic Stem Cells Regional Outlook (Revenue, USD Million, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care include:

Cancer Stem Cell Therapeutics Market Global Cancer Stem Cell Therapeutics Market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191218005455/en/

Contacts

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.com Website: https://www.technavio.com

See the original post here:
Global Allogeneic Stem Cells Market 2020-2024 | Evolving Opportunities with Biosolution Co. Ltd. and Cynata Therapeutics Ltd. | Technavio - Yahoo...